James Mullen

Sep 10, 2018

Thermo Fisher Scientific's board has elected James Mullen as a director, effective Nov. 8. He was appointed to the board's strategy and financing committee, and his term expires at the 2019 annual meeting. Mullen was CEO of Patheon until that firm's acquisition by Thermo Fisher in August 2017. Prior to Patheon, he was CEO and president of Biogen.